Floatz logo

Toripalimab

Second-line Treatment

Tianjin Medical University Cancer Institute and Hospitalmonoclonal_antibodyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Second-line Treatment cohort.

Asset / SponsorPhaseRating
Adebrelimab
Sun Yat-sen University
Phase 2CCC
Fruquintinib
Sun Yat-sen University
Phase 2CCC
Carboplatin
Second Affiliated Hospital of Zunyi Medical University
Phase 2CCC
Chir-258
Novartis Pharmaceuticals
Phase 2CCC

Same molecule, other indications

Toripalimab is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
ToripalimabDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →